Motley-Fool's monthly speculation on cancer treatment stocks
/3 Cancer Treatment Stocks to Buy in March
There has been tremendous progress in the battle against cancer, but it remains the second leading cause of death in the U.S., behind heart disease. That means there is plenty of work left to be done.
So which cancer-focused companies are worth watching? We asked three Motley Fool healthcare contributors to weigh in, and they called out Blueprint Medicines(NASDAQ:BPMC), Halozyme Therapeutics (NASDAQ:HALO), and Merck (NYSE:MRK).
